Enzalutamide-Induced Acute Maculopapular Rash in Treatment of Metastatic Prostate Cancer: First Case Report from a Tertiary Cancer Care Center of North India-Reference-Cited by-同舟云学术

Enzalutamide-Induced Acute Maculopapular Rash in Treatment of Metastatic Prostate Cancer: First Case Report from a Tertiary Cancer Care Center of North India

Published:2023-02-17 Issue:3 Volume:14 Page:571-575
ISSN:0975-7651
Container-title:Indian Journal of Surgical Oncology
language:en
Short-container-title:Indian J Surg Oncol

Author:

Chakraborty Arnab^ORCID,Khanna Ashish^ORCID,Vasudeo Vivek^ORCID,Pratihar Sarbartha Kumar^ORCID,Singh Amitabh^ORCID,Rawal Sudhir^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s13193-023-01719-7.pdf

Reference14 articles.

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512. https://doi.org/10.1056/NEJMoa040720

2. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 prevail study. Eur Urol 71(2):151–154. https://doi.org/10.1016/j.eururo.2016.07.032

3. Hong JH (2018) Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. Expert Opin Drug Metab Toxicol 14(3):361–369. https://doi.org/10.1080/17425255.2018.1440288

4. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCafrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1903835

5. Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration- resistant prostate cancer. N Engl J Med 378:2465–2474

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone/degarelix/enzalutamide;Reactions Weekly;2024-02-03